Insuman Basal (Insulin Human)

Insuman Basal provides basal insulin therapy for diabetes management.

• Type 1 diabetes mellitus: supplies long‑acting insulin to maintain fasting glucose levels.
• Type 2 diabetes mellitus: supplements endogenous insulin to improve overall glycaemic control.
• Diabetes requiring basal insulin supplementation: offers steady insulin coverage when oral agents are insufficient.

• Insulin human binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor’s tyrosine kinase activity. This triggers intracellular signaling that promotes glucose uptake, glycogen synthesis and inhibition of hepatic glucose production, thereby lowering circulating blood glucose concentrations.

Insuman Basal may cause adverse reactions typical of insulin therapy.

Common Side Effects

• Hypoglycaemia: low blood glucose episodes, especially if dosing is excessive.
• Injection site reactions: redness, swelling or itching at the injection site.
• Weight gain: increased adipose tissue due to improved glucose utilisation.
• Lipodystrophy: localized changes in subcutaneous fat with repeated injections.
• Edema: mild fluid retention in extremities.

Serious or Rare Side Effects

• Severe hypoglycaemia: neuroglycopenic symptoms requiring immediate assistance.
• Allergic reactions: urticaria, rash, or anaphylaxis.
• Insulin antibodies: may alter insulin effectiveness.
• Acute metabolic acidosis: rare but serious metabolic disturbance.
• Stevens‑Johnson syndrome: severe skin reaction, though extremely uncommon.

When using Insuman Basal, consider the following safety measures.

• Dose individualisation: adjust dose based on regular blood glucose monitoring.
• Hypoglycaemia risk: educate patients on recognising and treating low blood sugar.
• Concomitant illnesses: modify therapy during infection, surgery or renal/hepatic impairment.
• Pregnancy and lactation: use only if benefits outweigh potential risks; category not established.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Basal can interact with several drug classes.

Major Interactions (Avoid)

• Other insulin products: additive hypoglycaemic effect.
• Meglitinides (e.g., repaglinide): increased risk of severe hypoglycaemia.
• Beta‑blockers: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely)

• Oral antidiabetic agents (metformin, sulfonylureas): may potentiate glucose‑lowering effect.
• ACE inhibitors and ARBs: can enhance insulin sensitivity.
• Diuretics: may affect potassium levels influencing insulin action.
• Corticosteroids: may increase insulin requirements.
• Alcohol: can cause unpredictable glucose fluctuations.